AI in oncology: Fundamentals to full integration into your practice

Dr. Debra Patt is a practicing oncologist and breast cancer specialist in Austin, Texas, and an executive vice president of Texas Oncology with responsibilities in healthcare policy and strategic initiatives. She is an active leader in breast cancer and research in healthcare informatics driving digital healthcare tool adoption in clinical practice to improve the patient journey.

She is the managing partner for the central Texas, Gulf, and Rio Grande Valley regions in Texas Oncology since 2023. Dr. Patt is the medical director for public policy for The US Oncology Network and has testified before the US Congress and Senate to protect access to care for cancer patients. She has chaired the council on legislation and the cancer committee for the Texas Medical Association.

Dr. Patt serves as the current vice president of the Community Oncology Alliance and on the ASCO Board of Directors. She also chairs the Artificial Intelligence Task Force for ASCO and is the liaison for the clinical innovation committee.

She lectures medical students and is a professor at Dell Medical School at The University of Texas at Austin.

Dr. Sanjay Juneja is a triple board-certified hematologist and medical oncologist serving as Vice President of Clinical AI Operations at Tempus AI. In this role, he leads clinical AI strategy and implementation initiatives that bridge cutting-edge artificial intelligence with real-world oncology practice.

Dr. Juneja maintains an active clinical practice with Citrus Oncology while advancing the field through his expertise in AI applications in medicine. He completed Harvard's inaugural Executive Education program in AI in Healthcare: from Strategies to Implementation and serves on the Editorial Board of the peer-reviewed journal AI in Precision Oncology.
A Louisiana native, Dr. Juneja completed his undergraduate education at LSU's Honors College before pursuing his medical training at LSU Shreveport, where he served in leadership roles including medical school president and chief fellow, earning resident of the year honors annually.

His contributions to healthcare innovation have earned national recognition, including being named Targeted Oncology's inaugural 2024 Oncology Icon and receiving an invitation to the White House's 2023 Healthcare Leaders in Social Media Roundtable. He has been recognized as a 40 Under 40 recipient and selected as one of the Capital Region's Top 500 Most Influential Leaders for three consecutive years.

Dr. Juneja's insights on AI in healthcare have been featured in major publications including The Washington Post, WIRED, Bloomberg, and PBS. As founder of TensorBlack Inc., an AI education and consulting company focused on oncology applications, he continues to advance the integration of artificial intelligence in clinical practice.

Through his platform as "TheOncDoc," Dr. Juneja has built a global following of over 750,000 healthcare professionals and researchers, translating complex AI and oncology concepts for clinical audiences. His podcast series on AI and healthcare reaches practitioners in over 100 countries, fostering international dialogue on the future of technology-enabled medicine

Dr. Cynthia Ma is Professor of Medicine within the Division of Oncology, Department of Medicine, at Washington University School of Medicine, in St. Louis, MO. She is a breast oncologist and a physician scientist, whose research focuses on endocrine therapy and targeted agents for the treatment of breast cancer. She has led several biomarker directed, investigator initiated trials including neoadjuvant studies of endocrine agents in combination with inhibitors against PI3K pathway or the CDK4/6 in patients with locally advanced estrogen receptor positive breast cancer. She is the study chair for the ongoing ALLIANCE ALTERNATE trial, which evaluates Ki67 based biomarkers as well as genomic predictors of endocrine responsiveness and a member of the Alliance Breast Committee. Dr. Ma is the clinical director of the Breast Cancer Program in Medical Oncology at Washington University School of Medicine; Co-leader of the Breast Cancer Focus Group and Breast Cancer Research Program at Siteman Cancer Center located in St. Louis, MO. She is a member of multiple scientific and research committees; Section Editor for Current Breast Cancer Report and serves as an Editorial Board Member on several major journals. Dr. Ma was recently elected as the Vice President of CAHON (Chinese American Hematologist and Oncologist Network).

Dr. Cohen is a leading medical oncologist and cancer researcher who brings a unique combination of extensive clinical and research experience to Tempus’ leadership team. He was most recently the Chief of the Division of Hematology-Oncology as well as the Associate Director of Clinical Science at UC San Diego (UCSD) Moores Cancer Center. Dr. Cohen also led the Precision Immunotherapy Clinic and co-directed the San Diego Center for Precision Immunotherapy at UCSD. Before UCSD, Dr. Cohen spent 15 years at the University of Chicago, where he was the co-director of the Head and Neck Cancer Program as well as Hematology/Oncology Fellowship Program Director.